NCT07218809 2026-01-16
TREVI-OC-01
AstraZeneca
Phase 3 Recruiting
Clinical Trials
38 trialsNCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT06994195 2025-08-17
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT00028743 2020-04-02
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00652691 2019-04-08
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Mayo Clinic
Phase 1 Completed
NCT00114166 2018-07-24
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00005029 2018-04-12
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00287859 2017-11-29
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00314678 2016-12-08
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
University of California, Irvine
Phase 2 Completed
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01630018 2016-09-22
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
Chong Kun Dang Pharmaceutical
Phase 2 Completed
NCT00045175 2016-06-23
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
University Health Network, Toronto
Phase 1 Completed
NCT00006454 2015-12-23
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
AGO Study Group
Phase 3 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00313612 2015-11-27
Oxaliplatin and Topotecan in Advance Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00072267 2015-07-23
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01690598 2015-06-10
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Vejle Hospital
Phase 1/2 Completed
NCT00550784 2014-10-07
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00436644 2014-04-16
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Mayo Clinic
Phase 2 Completed
NCT00003064 2014-01-06
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003733 2013-09-20
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003732 2013-08-12
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00014690 2013-08-02
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00055614 2013-06-26
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003967 2013-05-27
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00005026 2013-05-27
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00842452 2013-04-05
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00002913 2013-01-24
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005051 2012-11-09
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NYU Langone Health
Phase 2 Completed
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00231855 2012-04-24
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Montefiore Medical Center
Phase 2 Completed
NCT00006391 2011-04-05
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NYU Langone Health
Phase 1 Completed
NCT00003297 2011-03-24
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
Georgetown University
Phase 1/2 Completed
NCT00217555 2010-09-21
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed